Sign in
Taking people in United StatesPhase 2

GLP-1R Agonist Treatment for Opioid Use Disorder

Key facts

Who runs it
Milton S. Hershey Medical Center
Where
Baltimore, Fall River, Harrisburg, and New York, United StatesSee the 4 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
27 Jan 2025
Expected to end
30 Apr 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Semaglutide Pen Injector
  • Placebo
Record updated
17 November 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Age 18 to 75 years
  • Body mass index (BMI) > 18
  • Able and willing to provide informed consent prior to any study-related activities
  • Current diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 Opioid Use Disorder (OUD) as per the Mini International Neuropsychiatric Interview (MINI) or per the site clinic diagnosis. Patients are eligible if they have a MINI > 3 ("moderate" or "severe" in the "Specify If" box in the Substance Use Disorder (Non-Alcohol) module for the category of opiates)
  • Currently receiving outpatient treatment for OUD and at least 2 weeks on buprenorphine (BUP) or 4 weeks on methadone at the study site and/or at an associated clinic at the time of enrollment
  • Have at least 1 urine test positive for opioids after 2 weeks on BUP or 4 weeks on methadone
  • Have positive self-reporting of opioid use after 2 weeks on BUP or 4 weeks on methadone
  • If capable of becoming pregnant and of childbearing age, is not pregnant (confirmed) or breastfeeding at the time of enrollment and agrees to use a medically accepted method of birth control or or to abstain from sexual activity that could result in pregnancy (if applicable) while in the study
  • Able to read and communicate in English to the level required to accept standard care and complete all study requirements
  • Able and willing to engage/adhere to the entirety of the study protocol (19 weeks)
  • Not currently a prisoner

Who cannot take part

  • Past 30-day use of Sincalide, Sulfonylureas, insulin and insulin products or other medications that may interact with semaglutide
  • End stage liver disease or previous liver transplant
  • Treatment with any investigational drug in the one month preceding the study
  • Previous randomization for participation in this trial
  • Plans for travel outside of the local area over the 19 weeks (1 week of baseline, 12 weeks of medication, 1 week wash-out, and follow-up after a further 28 days) that would interfere with visits during the study period or other logistic factors that would make it difficult to commit to the entire duration of study
  • History of angioedema, serious hypersensitivity reaction, or anaphylactic reaction to semaglutide or another GLP-1R agonist
  • Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome Type 2 (MEN 2) or thyroid nodule
  • Type 1 diabetes or history of diabetic ketoacidosis
  • Type 2 diabetes mellitus or current use of a dipeptidyl peptidase-4 (DPP-4) inhibitor
  • Current or past diagnosis of pancreatitis, gastroparesis, or other severe gastrointestinal (GI) disease
  • Current or past diagnosis of gallbladder disease or gallstones
  • Serious cardiovascular disease within the past 6 months (e.g. uncontrolled hypertension, heart failure, significant cardiac arrhythmias, myocardial infarction, presence of angina pectoris, symptomatic coronary artery disease, deep vein thrombosis, pulmonary embolism, second- or third-degree heart block, mitral valve or aortic stenosis, hypertrophic cardiomyopathy, stroke)
  • Severe co-occurring psychiatric disorder (e.g., bipolar disorder, psychotic disorder, schizophrenia), and/or history or evidence of organic brain disease or dementia that would compromise safety or compliance with the study protocol in the opinion of the site principal investigator (PI) and/or physician. As there is no specific scale that determines this, this will include the Site PI/physician determining if the potential participant shows consistency in decision making and if they are alert and oriented to time, date, day and location
  • Significant risk of suicide requiring a different/higher level of care, according to the clinical judgment of the study physician or site principal investigator, or history of suicide attempts within the past 1 year, unless participation is cleared by clinician assessment and/or judgment. A Columbia-Suicide Severity Rating Scale (C-SSRS) indicating a history of suicide attempts within the past year, or active suicidal ideation within the past 1 month, will qualify as significant risk of suicide
  • Any other condition at screening that precludes safe participation in the trial in the judgment of the site PI or study physician
  • Hypoglycemia on intake visit (blood glucose < 60 mg/dL)
  • End-stage renal failure, on dialysis, or glomerular filtration rate (GFR) <30 mL/min per 1.73 square meters or previous renal transplant
  • Age < 18 or > 75 years
  • BMI <18
  • Individuals who are pregnant, planning pregnancy, breastfeeding, or unwilling to use adequate contraceptive measures
  • Current use of glucagon-like peptide 1 receptor (GLP-1R) agonist
  • Any contraindication to both methadone and BUP
  • Any contraindication to a GLP-1R agonist
  • Currently a prisoner

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in United States.

  • University of Maryland, BaltimoreBaltimore, United StatesContact: Jennifer Nyland, PhDNo longer taking part
  • Stanley Street Treatment and ResourcesFall River, United StatesContact: Research HotlineTaking people
  • Advancement in Recovery (AIR) Program (formerly known as PPI)Harrisburg, United StatesContact: Subi UpadhyayTaking people
  • NYU Langone HealthNew York, United StatesContact: Mat KladneyTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is:

Read full original descriptionShow less

• Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids?

The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids.

The participants will:

* Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study

The 2 groups in the trial

  • Investigational groupTreatment being tested

    Participants randomized to semaglutide will be started at a low dose (0.25 mg once per week) which will be gradually increased weekly until 1.0 mg is reached at Week 4 of the intervention.

    Treatment: Semaglutide Pen Injector

  • Control groupPlacebo, for comparison

    Participants in the control group will have placebo administered once per week.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06548490, who can take part
Publications
Record updated
17 November 2026